The invention provides a pharmaceutical combination including an αvβ1 integrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders. The at least one additional therapeutic agent may be a farnesoid X receptor (FXR) agonist. For example, the pharmaceutical combination includes (S)-2-(4-methyltetrahydro-2H-pyran-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid (Compound 1) and 2-[3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1, 3-ben-zothiazole-6-carboxylic acid (tropifexor).

The invention relates to novel compounds of the general formula (I),

##STR00001##

with Het-2 being an optionally substituted bicyclic heteroaryl of the formula

##STR00002##

pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

The invention relates to novel compounds of the general formula (I),

##STR00001##

with Het-2 being an optionally substituted bicyclic heteroaryl of the formula

##STR00002##

pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

A non-cellular root canal filler comprises a tetrahydroisoquinoline compound or a pharmaceutically acceptable salt thereof, or a solvate of the compound or the salt, and a dental tissue regeneration promotion kit comprises a pretreatment agent comprising a serine protease, and the non-cellular root canal filler.

A non-cellular root canal filler comprises a tetrahydroisoquinoline compound or a pharmaceutically acceptable salt thereof, or a solvate of the compound or the salt, and a dental tissue regeneration promotion kit comprises a pretreatment agent comprising a serine protease, and the non-cellular root canal filler.

Disclosed is a macrocyclic kinase inhibitor, wherein the compound, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is as shown in formula I. Experiments show that the new compound as shown in formula I disclosed in the present invention exhibits an excellent TRK inhibitory activity, has a significant inhibitory effect on TRKA-mutant cell growth, and exhibits an excellent inhibitory effect on in vivo tumor growth, thus providing a new choice for the clinical treatment of diseases associated with abnormal TRK activity.

In various implementations, cannabidiol, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to improve the health of the individual. The beta-hydroxybutyrate may include R-beta-hydroxybutyrate. The beta-hydroxybutyrate may include a salt and a polymer of beta-hydroxybutyrate. Other compounds may include amino acids, fatty acids or esters thereof, and/or combinations thereof.

In various implementations, cannabidiol, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to improve the health of the individual. The beta-hydroxybutyrate may include R-beta-hydroxybutyrate. The beta-hydroxybutyrate may include a salt and a polymer of beta-hydroxybutyrate. Other compounds may include amino acids, fatty acids or esters thereof, and/or combinations thereof.

The present disclosure relates to compositions of phytonutrients and methods of treating diabetes by administering these compositions to subjects in need thereof. The compositions described herein are rationally designed compositions of phytonutrients that promote insulin sensitivity and have weight-loss potential. The compositions include formulation of rationally combined phytonutrients for diabetes treatment and management. Using nanofluidic proteomics, phytonutrients were classified as insulin sensitizing or anti-adipogenic based on their ability to enhance insulin-stimulated Akt2 phosphorylation and glucose uptake or inhibit adipogenesis, respectively. In some embodiments, the formulation includes a synergistic amount of insulin-sensitizing phytonutrients cinnamaldehyde and curcumin.

The present disclosure relates to compositions of phytonutrients and methods of treating diabetes by administering these compositions to subjects in need thereof. The compositions described herein are rationally designed compositions of phytonutrients that promote insulin sensitivity and have weight-loss potential. The compositions include formulation of rationally combined phytonutrients for diabetes treatment and management. Using nanofluidic proteomics, phytonutrients were classified as insulin sensitizing or anti-adipogenic based on their ability to enhance insulin-stimulated Akt2 phosphorylation and glucose uptake or inhibit adipogenesis, respectively. In some embodiments, the formulation includes a synergistic amount of insulin-sensitizing phytonutrients cinnamaldehyde and curcumin.